Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377

Daniel E Spratt¹, Vinnie Y T Liu², Jeff Michalski³, Elai Davicioni², Alejandro Berlin⁴, Jeffry P Simko⁵, Jason A Efstathiou⁶, Phuoc T Tran⁷, Howard M Sandler⁸, William A Hall⁹, Darby J S Thompson², Matthew B Parliament¹⁰, Ian S Dayes¹¹, Rohann Jonathan Mark Correa¹², John M Robertson¹³, Elizabeth M Gore¹⁴, Desiree E Doncals¹⁵, Eric Vigneault¹⁶, Luis Souhami¹⁷, Theodore G Karrison¹⁸, Felix Y Feng¹⁹

Affiliations

¹ Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio. Electronic address: Daniel.Spratt@uhhospitals.org.
² Veracyte, Inc, South San Francisco, California.
³ Department of Radiation Oncology, Washington University, St. Louis, Missouri.
⁴ Princess Margaret Cancer Centre, Cancer Clinical Research Unit, Toronto, Ontario, Canada.
⁵ Department of Pathology, UCSF Medical Center-Mount Zion, San Francisco, California.
⁶ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
⁷ Department of Pathology, University of Maryland, Baltimore, Maryland.
⁸ Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
⁹ Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
¹⁰ Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
¹¹ Division of Radiation Oncology, Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada.
¹² Department of Oncology, London Regional Cancer Program, London, Ontario, Canada.
¹³ Department of Radiation Oncology, Beaumont Health CCOP, Royal Oak, Michigan.
¹⁴ Department of Radiation Oncology, Milwaukee VA Medical Center, Milwaukee, Wisconsin.
¹⁵ Division of Radiation Oncology, Akron City Hospital, Akron, Ohio.
¹⁶ Department of Radiation Oncology, CHU de Quebec Universite Laval, Quebec, Quebec, Canada.
¹⁷ Department of Radiation Oncology, Cedars Cancer Centre, McGill University, Montreal, Quebec, Canada.
¹⁸ NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.
¹⁹ Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

PMID: 39320298
PMCID: PMC11698260
DOI: 10.1016/j.ijrobp.2024.08.044

Published Erratum

Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377

Daniel E Spratt et al. Int J Radiat Oncol Biol Phys. 2024.

. 2024 Dec 1;120(5):1461.

doi: 10.1016/j.ijrobp.2024.08.044. Epub 2024 Sep 23.

Authors

Affiliations

¹ Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio. Electronic address: Daniel.Spratt@uhhospitals.org.
² Veracyte, Inc, South San Francisco, California.
³ Department of Radiation Oncology, Washington University, St. Louis, Missouri.
⁴ Princess Margaret Cancer Centre, Cancer Clinical Research Unit, Toronto, Ontario, Canada.
⁵ Department of Pathology, UCSF Medical Center-Mount Zion, San Francisco, California.
⁶ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
⁷ Department of Pathology, University of Maryland, Baltimore, Maryland.
⁸ Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
⁹ Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
¹⁰ Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
¹¹ Division of Radiation Oncology, Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada.
¹² Department of Oncology, London Regional Cancer Program, London, Ontario, Canada.
¹³ Department of Radiation Oncology, Beaumont Health CCOP, Royal Oak, Michigan.
¹⁴ Department of Radiation Oncology, Milwaukee VA Medical Center, Milwaukee, Wisconsin.
¹⁵ Division of Radiation Oncology, Akron City Hospital, Akron, Ohio.
¹⁶ Department of Radiation Oncology, CHU de Quebec Universite Laval, Quebec, Quebec, Canada.
¹⁷ Department of Radiation Oncology, Cedars Cancer Centre, McGill University, Montreal, Quebec, Canada.
¹⁸ NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.
¹⁹ Department of Radiation Oncology, University of California San Francisco, San Francisco, California.

PMID: 39320298
PMCID: PMC11698260
DOI: 10.1016/j.ijrobp.2024.08.044

No abstract available

PubMed Disclaimer

Erratum for

Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.
Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Spratt DE, et al. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):370-377. doi: 10.1016/j.ijrobp.2023.04.010. Epub 2023 May 2. Int J Radiat Oncol Biol Phys. 2023. PMID: 37137444 Free PMC article. Clinical Trial.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Affiliations

Authors

Affiliations

Erratum for

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous